Is TRAIL hepatotoxic?

Hepatology

Volumn 34, Issue 1, 2001, Pages 3-6

  Gores, G J ^a   Kaufmann, S H ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; RECEPTOR; TRAIL RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CELL SURVIVAL; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034949983     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.25173a     Document Type: Review

References (41)

1. Apoptosis by death factor
2. Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction
3. Lethal effect of the anti-Fas antibody in mice
4. Cytokine-mediated hepatic apoptosis
5. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
6. Identification and characterization of a new member of the TNF family that induces apoptosis
7. Apoptosis induced by death receptors
8. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
9. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
10. Expression and antitumor effects of TRAIL in human cholangiocarcinoma
11. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines
12. Safety and antitumor activity of recombinant soluble Apo2 ligand
13. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
14. Steering anti-cancer drugs away from the TRAIL
15. TRAIL: A molecule with multiple receptors and control mechanisms
16. The TRAIL to selective tumor death
17. The TRAIL of death
18. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
19. Functional analysis of TRAIL receptors using monoclonal antibodies
20. Induction of apoptosis of RA synovial cells by a novel antihuman DR5 antibody
21. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas
22. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
23. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
24. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
25. FADD/MORT-and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
26. FADD is required for DR4-and DR5-mediated apoptosis: Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts
27. The TRAIL discussion: It is FADD and caspase-8!
28. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
29. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
30. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand
31. From bench to clinic with apoptosis-based therapeutic agents
32. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation
33. In vitro hepatocyte toxicity of Apo2L/TRAIL is associated with aberrant biochemical properties of nonoptimized recombinant soluble ligand preparations
34. A tale of three TRAILS: Choosing the best therapeutic path to avoid premature apoptosis of normal epidermal cells
35. Parallel decrease of Na(+)-taurocholate cotransport and its encoding mRNA in primary cultures of rat hepatocytes
36. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: Implications for the regulation of apoptosis in liver endothelial cells
37. Fas-mediated apoptosis in primary cultured mouse hepatocytes
38. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
39. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
40. Molecular determinants of response to TRAIL in killing of normal and cancer cells
41. Antileukemic drugs increase death receptor 5 levels and enhance Apo2L-induced apoptosis of human acute leukemia cells